First-Line Pembrolizumab Versus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer: KEYNOTE-024 Japan Subset

Lung Cancer
15/09/2020

Cancer Sci. 2020 Sep 14. doi: 10.1111/cas.14647. Online ahead of print.

ABSTRACT

This prespecified subanalysis of the global, randomized controlled phase 3 KEYNOTE-024 study of pembrolizumab versus chemotherapy in previously untreated metastatic non-small-cell lung cancer without EGFR/ALK alterations and a PD-L1 tumor proportion score ≥50% evaluated clinical outcomes among patients enrolled in Japan. Treatment consisted of pembrolizumab 200 mg every 3 weeks (35 cycles) or platinum-based chemotherapy (4-6 cycles). The primary endpoint was progression-free survival; secondary


endpoints included overall survival and safety. Of 305 patients randomized in KEYNOTE-024 overall, 40 patients were enrolled in Japan (all received treatment: pembrolizumab, n = 21; chemotherapy, n = 19). Median progression-free survival was 41.4 (95% CI, 4.2-42.5) with pembrolizumab and 4.1 (95% CI, 2.8-8.3) months with chemotherapy (HR, 0.27 [95% CI, 0.11-0.65]; one-sided, nominal P=0.001). Median overall survival was not reached (95% CI, 22.9-NR) and 21.5 (95% CI, 5.2-35.0) months, respectively (HR, 0.39 [95% CI, 0.17-0.91]; one-sided, nominal P=0.012). Treatment-related adverse events occurred in 21/21 (100%) pembrolizumab-treated and 18/19 (95%) chemotherapy-treated patients; 8 patients (38%) and 9 patients (47%), respectively, had grade 3-5 events. Immune-mediated adverse events and infusion reactions occurred in 11 patients (52%) and 4 patients (21%), respectively; 4 patients (19%) and 1 patient (5%), respectively, had grade 3-5 events. Consistent with results from KEYNOTE-024 overall, first-line pembrolizumab improved progression-free survival and overall survival versus chemotherapy with manageable safety among Japanese patients with metastatic non-small-cell lung cancer without EGFR/ALK alterations and a PD-L1 tumor proportion score ≥50%. The trial is registered with Clinicaltrials.gov: NCT02142738.